BioCentury
ARTICLE | Clinical News

Defactinib: Phase II suspended enrollment

October 5, 2015 7:00 AM UTC

Verastem stopped enrollment in the double-blind, international, pivotal Phase II COMMAND trial in patients with MPM after a pre-planned interim analysis showed that twice-daily 400 mg oral defactinib ...